Factors associated with hepatitis C and HIV testing uptake among men who inject image and performance enhancing drugs.

INTRODUCTION AND AIMS Historically, people who inject image and performance enhancing drugs (IPED) were not perceived as being at high risk of HIV or hepatitis C virus (HCV) infection. However, recent studies indicate HCV and HIV prevalences are elevated, with many HCV infections undiagnosed. DESIGN AND METHODS Men who inject IPEDs recruited from community settings and specialist services, including needle-syringe programs, across UK during 2016 self-completed a questionnaire. Multivariate analyses examined factors associated with HCV/HIV testing. RESULTS The participants' (n=562; 24% service recruited) median age was 31 years, 4% identified as gay or bisexual, 18% had ever been imprisoned and 6% had ever injected a psychoactive drug. Those community recruited more often reported sharing drugs vials (16% vs. 8%, P=0.021) and, among those with 2+ sexual partners, poor condom use (50% vs. 36%, P=0.063), than those service recruited. Overall, one-third had ever been tested for HCV (31%) and/or HIV (34%). Testing uptake was associated with other risk factors for HCV/HIV, being recruited through services and having received metabolic tests. Participants' motivations for using IPEDs were associated with recruitment setting and HIV/HCV testing uptake. DISCUSSION AND CONCLUSIONS The majority were untested for HCV/HIV. HCV/HIV testing and risks were associated with recruitment through services. Previous needle and syringe program-based studies have potentially overestimated testing uptake and underestimated risk. Targeted interventions are needed, particularly for those not accessing services. The association between HCV/HIV testing uptake and receipt of metabolic tests suggests that developing a combined offer of these tests as part of health monitoring could improve uptake.

[1]  B. Larance,et al.  Health Care Engagement Behaviors of Men who Use Performance- and Image-Enhancing Drugs in Australia , 2019, Substance abuse.

[2]  S. Fraser,et al.  Is another relationship possible? Connoisseurship and the doctor-patient relationship for men who consume performance and image-enhancing drugs. , 2019, Social science & medicine.

[3]  Steven Keen,et al.  Support for people who use Anabolic Androgenic Steroids: A Systematic Scoping Review into what they want and what they access , 2019, BMC Public Health.

[4]  V. Hope,et al.  Infections and risk among people who use image and performance enhancing drugs , 2019, Human Enhancement Drugs.

[5]  W. Waring,et al.  Pharmacological effects and safety monitoring of anabolic androgenic steroid use: differing perceptions between users and healthcare professionals , 2019, Therapeutic advances in drug safety.

[6]  L. Westlye,et al.  Cognitive Performance and Structural Brain Correlates in Long-Term Anabolic-Androgenic Steroid Exposed and Nonexposed Weightlifters , 2019, Neuropsychology.

[7]  R. Ralphs,et al.  Polydrug use and polydrug markets amongst image and performance enhancing drug users: Implications for harm reduction interventions and drug policy. , 2019, The International journal on drug policy.

[8]  H. Wand,et al.  Health risk and health seeking behaviours among people who inject performance and image enhancing drugs who access needle syringe programs in Australia. , 2018, Drug and alcohol review.

[9]  J. McVeigh,et al.  Identifying a typology of men who use anabolic androgenic steroids (AAS). , 2018, The International journal on drug policy.

[10]  J. Parry,et al.  Low levels of hepatitis C diagnosis and testing uptake among people who inject image and performance enhancing drugs in England and Wales, 2012-15. , 2017, Drug and alcohol dependence.

[11]  J. Copeland,et al.  Risk and blood‐borne virus testing among men who inject image and performance enhancing drugs, Sydney, Australia , 2017, Drug and alcohol review.

[12]  J. McVeigh,et al.  Anabolic steroids in the UK: an increasing issue for public health , 2017 .

[13]  H. Pope,et al.  Polypharmacy, Infectious Diseases, Sexual Behavior, and Psychophysical Health Among Anabolic Steroid-Using Homosexual and Heterosexual Gym Patrons in San Francisco's Castro District , 2017, Substance use & misuse.

[14]  T. Kaufmann,et al.  Brain connectivity aberrations in anabolic-androgenic steroid users , 2016, NeuroImage: Clinical.

[15]  F. McKay,et al.  Do performance and image enhancing drug users in regional Queensland experience difficulty accessing health services? , 2016, Drug and alcohol review.

[16]  J. McVeigh,et al.  Access to needle and syringe programs by people who inject image and performance enhancing drugs. , 2016, The International journal on drug policy.

[17]  Ross J. Harris,et al.  Risk of HIV and Hepatitis B and C Over Time Among Men Who Inject Image and Performance Enhancing Drugs in England and Wales: Results From Cross-Sectional Prevalence Surveys, 1992–2013 , 2016, Journal of acquired immune deficiency syndromes.

[18]  I. van Beek,et al.  Performance and image enhancing drug injectors' access to needle syringe programs: Responding to a public policy dilemma. , 2015, The International journal on drug policy.

[19]  T. Hildebrandt,et al.  Healthcare professionals' stigmatization of men with anabolic androgenic steroid use and eating disorders. , 2015, Body image.

[20]  J. McVeigh,et al.  Polypharmacy among anabolic-androgenic steroid users: a descriptive metasynthesis , 2015, Substance Abuse Treatment, Prevention, and Policy.

[21]  J. McVeigh,et al.  Variability and dilemmas in harm reduction for anabolic steroid users in the UK: a multi-area interview study , 2014, Harm Reduction Journal.

[22]  R. Wood,et al.  Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. , 2014, Endocrine reviews.

[23]  F. McKay,et al.  Steroid users and the unique challenge they pose to needle and syringe program workers. , 2014, Drug and alcohol review.

[24]  S. Zeuzem,et al.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection. , 2014, Journal of hepatology.

[25]  J. Parry,et al.  Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study , 2013, BMJ Open.

[26]  H. Wand,et al.  Are people who inject performance and image-enhancing drugs an increasing population of Needle and Syringe Program attendees? , 2013, Drug and alcohol review.

[27]  Tonya Dodge,et al.  The use of anabolic androgenic steroids and polypharmacy: a review of the literature. , 2011, Drug and alcohol dependence.

[28]  R. Coomber,et al.  Injecting drug users: a stigmatised and stigmatising population. , 2009, The International journal on drug policy.

[29]  C. Day,et al.  Blood-borne virus prevalence and risk among steroid injectors: results from the Australian Needle and Syringe Program Survey. , 2008, Drug and alcohol review.

[30]  J. Elford,et al.  Use of anabolic steroids and associated health risks among gay men attending London gyms. , 2002, Addiction.

[31]  J. Parry,et al.  The risk of infection with HIV and hepatitis B in individuals who inject steroids in England and Wales , 1998, Epidemiology and Infection.

[32]  J. de Irala,et al.  Reliability of self-reported human immunodeficiency virus risk behaviors in a residential drug treatment population. , 1996, American journal of epidemiology.

[33]  D. Vlahov,et al.  Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. , 1993, Addiction.